ILEVRO

This brand name is authorized in Canada, Ecuador, New Zealand, United States, South Africa

Active ingredients

The drug ILEVRO contains one active pharmaceutical ingredient (API):

1 Nepafenac
UNII 0J9L7J6V8C - NEPAFENAC

Nepafenac is a non-steroidal anti-inflammatory and analgesic prodrug. After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a nonsteroidal anti-inflammatory drug. Amfenac inhibits the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.

Read about Nepafenac

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
ILEVRO Ophthalmic suspension FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
S01BC10 Nepafenac S Sensory organs → S01 Ophthalmologicals → S01B Antiinflammatory agents → S01BC Antiinflammatory agents, non-steroids
Discover more medicines within S01BC10

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02411393
Country: EC Agencia Nacional de Regulaciรณn, Control y Vigilancia Sanitaria Identifier(s): 383-MEE-0714
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 17328
Country: US FDA, National Drug Code Identifier(s): 0065-1750
Country: ZA Health Products Regulatory Authority Identifier(s): 52/15.4/0575

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.